Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 12 and up

Therapeutic drug monitoring-guided SSRI dosing for hospitalized teens and adults

Official title: Therapeutic Drug Monitoring-Guided Treatment With Sertraline, or Escitalopram in Hospitalized Adults and Children

Run by Poznan University of Medical Sciences · NCT07478796 · Data updated 2026-11-12

This project will test whether using blood-level monitoring (TDM) to guide dosing of fluoxetine, escitalopram, or sertraline helps hospitalized patients aged 12 and older with moderate to severe depression.

More Depression - Major Depressive Disorder trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages12 Years and up
SexAll
Enrollment180 (estimated)
SponsorPoznan University of Medical Sciences
Academic / other
Locations1 site (Poznan, Greater Poland Voivodeship)
StatusRecruiting
StartedApril 3, 2025
Main results expectedNovember 30, 2027
Study endsNovember 30, 2027
Registry record updatedMarch 18, 2026
Trial IDNCT07478796 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are hospitalized patients aged 12 or older with a moderate to severe depressive episode who require SSRI treatment and can provide informed consent (with guardian consent as needed).

Probably not a fit

People with other primary psychiatric disorders (such as bipolar disorder or schizophrenia), active pregnancy or breastfeeding, unstable severe medical conditions, or those already on an adequate SSRI dose are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, head-to-head trial compares fluoxetine, escitalopram, and sertraline in patients aged 12 and older using prospective therapeutic drug monitoring (TDM) across all arms. The protocol includes dense plasma sampling, pharmacogenetic profiling, and population PK/PD model development to characterize exposure-efficacy and exposure-safety relationships. Primary aims are to derive model-based therapeutic concentration ranges and practical individualized dosing recommendations; secondary analyses will compare effectiveness, tolerability, and time-to-response among the three agents. The study is conducted at Poznan University of Medical Sciences and focuses on hospitalized youth and young adults with moderate to severe depressive episodes.

Why it matters

Potential benefit: If successful, this could provide practical individualized dosing ranges and TDM guidance to improve SSRI effectiveness and reduce side effects in adolescents and young adults.

How similar studies have gone: Previous TDM and PK/PD studies in adults have suggested exposure-response relationships for some SSRIs, but randomized, pediatric-focused head-to-head trials that combine dense sampling and pharmacogenetics are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male or female gender.
* Age 12 years or older.
* Diagnosis of moderate or severe depressive episode requiring SSRI treatment (fluoxetine, escitalopram, or sertraline).
* Written informed consent provided by patient and/or legal guardian.
* Women of childbearing potential must agree to use effective contraception or sexual abstinence.

Exclusion Criteria:

* Pregnancy, breastfeeding, or planning pregnancy.
* Diagnosis of other mental disorders (schizophrenia, bipolar disorder, intellectual disability).
* Decompensated severe somatic disorders (e.g., endocrine disorders, asthma exacerbation, hepatic/renal failure).
* Treatment with fluoxetine, sertraline, or escitalopram at an adequate dose for at least 4 weeks for the current episode (unless washout of 5x half-life is observed).
* Use of medications with high risk of CYP enzyme interactions.

Where it's running

  • Szpital Kliniczny im. Karola Jonschera UMP (Poznan University of Medical Sciences)
    Poznan, Greater Poland Voivodeship, Poland
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.